Increasing Geriatric Population In The Anti-Parkinson Drugs Market: Critical Driver Shaping the Anti-Parkinson Drugs Market in 2025

Increasing Geriatric Population In The Anti-Parkinson Drugs Market: Critical Driver Shaping the Anti-Parkinson Drugs Market in 2025Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Anti-Parkinson Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market for anti-Parkinson drugs has witnessed significant expansion in the past few years. The market size is projected to increase from $10.37 billion in 2024 to $11.08 billion in 2025, with a compound annual growth rate (CAGR) of 6.9%. The growth experienced in the historical period is due to factors such as an aging population, rise in disease prevalence, improvements in healthcare infrastructure, and advancements in medical research.

Anti-Parkinson Drugs Market Size Forecast: What's the Projected Valuation by 2029?
The market for anti-Parkinson drugs is set to experience robust growth in the upcoming years, expanding to a sizeable $13.73 billion by 2029, with a Compound Annual Growth Rate (CAGR) of 5.5%. The projected growth during this period is primarily due to increased awareness about the disease, advancements in biotechnology, and the rise in emerging markets. The predicted trends for this period encompass several factors such as greater investment in research and development, personalized medical treatments, therapies that modify the disease, drug repurposing, the advent of telemedicine and remote monitoring, the development of biosimilars, and collaborative research endeavours.

View the full report here:
https://www.thebusinessresearchcompany.com/report/anti-parkinson-drugs-global-market-report

What Are the Drivers Transforming the Anti-Parkinson Drugs Market?
The rise in the elderly population, coupled with an increase in instances of Parkinson's disease (PD), is anticipated to bolster the demand for anti-Parkinson medications. PD primarily manifests in individuals past the age of 60. For example, in October 2022, the World Health Organization, a US-based health institution, reported that by 2030, 1 in every 6 individuals globally will be 60 years or older. Furthermore, by 2050, the number of people in this age category is expected to reach 2.1 billion. This growth in the ageing population thus propels the expansion of the anti-Parkinson drugs market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3462&type=smp

What Long-Term Trends Will Define the Future of the Anti-Parkinson Drugs Market?
Major firms in the anti-Parkinson drugs market are prioritizing the development of innovative therapeutic approaches such as motor fluctuations and dyskinesia to improve symptom management and reduce adverse effects. Motor fluctuations and dyskinesia can exacerbate the treatment complexities of Parkinson's disease, impacting a patient's quality of life. For example, in January 2024, AbbVie Inc., an American pharmaceutical corporation, introduced PRODUODOPA. This is the first 24-hour subcutaneous infusion therapy designed for advanced Parkinson's disease, targeting severe motor fluctuations and dyskinesia when other methods are ineffective. It continuously administers levodopa, potentially enhancing the 'on' period and augmenting symptom control.

Which Segments in the Anti-Parkinson Drugs Market Offer the Most Profit Potential?
The anti-parkinson drugs market covered in this report is segmented -

1) By Drugs Class: Levodopa Or Carbidopa, Dopamine Receptor Agonists, Monoamine Oxidase Type B (MAO-B) Inhibitors, Catechol-O-Methyltransferase (COMT)-inhibitors, Anticholinergics, Other Drugs
2) By Route of Administration: Oral, Injection, Transdermal
3) By Distribution Channel: Hospital Pharmacies, Retailer Pharmacies, Online Pharmacies

Subsegments:
1) By Levodopa Or Carbidopa: Immediate-Release Levodopa Or Carbidopa, Extended-Release Levodopa Or Carbidopa
2) By Dopamine Receptor Agonists: Pramipexole, Ropinirole, Rotigotine
3) By Monoamine Oxidase Type B (MAO-B) Inhibitors: Selegiline, Rasagiline, Safinamide
4) By Catechol-O-Methyltransferase (COMT)-Inhibitors: Entacapone, Tolcapone
5) By Anticholinergics: Benztropine, Trihexyphenidyl
6) By Other Drugs: Amantadine, Apomorphine

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=3462&type=smp

Which Firms Dominate the Anti-Parkinson Drugs Market by Market Share and Revenue in 2025?
Major companies operating in the anti-parkinson drugs market include GlaxoSmithKline plc, Pfizer Inc., Merck Co., Novartis AG, F. Hoffmann-La Roche AG, UCB S.A, Teva Pharmaceutical Industries Ltd., AbbVie Inc., Mylan NV, C.H. Boehringer Sohn AG & Co. KG, Orion Pharma Ltd., ACADIA Pharmaceuticals Inc., Sun Pharmaceutical Industries Ltd., Wockhardt Ltd., Reddy's Laboratories Ltd., Intas Pharmaceuticals Ltd., US WorldMeds LLC, Zydus Lifesciences Limited, Chemical Industrial & Pharmaceutical Laboratories Ltd., Strides Shasun Ltd., Axcan Pharma Inc., Upsher-Smith Laboratories LLC, H. Lundbeck A/S, Vertical Pharmaceuticals LLC, Zambon SPA, M Somerset Pharmaceuticals Inc., Valeant Pharmaceuticals International Inc., Neurocrine Biosciences Inc., Supernus Pharmaceuticals Inc.

Which Regions Offer the Highest Growth Potential in the Anti-Parkinson Drugs Market?
North America was the largest region in the anti-Parkinson drugs market in 2023. Middle East is expected to be the fastest-growing region in the anti-parkinson drugs market during the forecast period. The regions covered in the anti-parkinson drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3462

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.